Does alpha1-antitrypsin augmentation therapy slow the annual decline in FEV1 in patients with severe hereditary alpha1-antitrypsin deficiency? Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL) alpha1-AT study group

Patients with severe hereditary alpha1-antitrypsin deficiency (alpha1-ATD) face a high risk of developing emphysema at a young age. Intravenous augmentation therapy with purified human alpha1-antitrypsin (alpha1-AT) is now available. However, a controlled trial to show its efficacy has never been carried out. The aim of this study was to compare the decline in forced expiratory volume in one second (deltaFEV1) between Danish patients who had never received augmentation therapy and German patients treated with weekly infusion of alpha1-AT. From the files of the Danish alpha1-ATD register, 97 exsmokers, with a PiZ phenotype and for whom results of at least two lung function measurements with an interval of at least 1 yr were available, were identified. From a German group of patients treated with weekly infusions of alpha1-AT, 60 mg x kg(-1) body weight, 198 exsmokers, with biannual lung function measurements were identified. The deltaFEV1 was compared between the two treatment groups by random effects modelling. The deltaFEV1 in the treated group was significantly lower than in the untreated group, with annual declines of 53 mL x yr(-1) (95% confidence interval (95% CI) 48-58 mL x yr(-1)) and 75 mL x yr(-1) (95% CI 63-87 mL x yr(-1)), respectively (p=0.02). The two groups differed with respect to gender and initial FEV1% predicted. Gender did not have any influence on the deltaFEV1. Stratification by initial FEV1% pred showed a significant effect of the treatment only in the group of patients with an initial FEV1% pred of 31-65%, and deltaFEV1 was reduced by 21 mL x yr(-1). This nonrandomized study suggests that weekly infusion of human alpha1-antitrypsin in patients with moderately reduced lung function may slow the annual decline in forced expiratory volume in one second.

This article has been cited by other articles:

				E. K. Silverman and R. A. Sandhaus Alpha1-Antitrypsin Deficiency N. Engl. J. Med., June 25, 2009; 360(26): 2749 - 2757. [Full Text] [PDF]

				J. B. Soriano and M. Miravitlles Your racing horses will help you to quit: a lesson for COPD and {alpha}1-antitrypsin deficiency research Eur. Respir. J., June 1, 2009; 33(6): 1244 - 1246. [Full Text] [PDF]

				P. A. Dawkins, C. L. Dawkins, A. M. Wood, P. G. Nightingale, J. A. Stockley, and R. A. Stockley Rate of progression of lung function impairment in {alpha}1-antitrypsin deficiency Eur. Respir. J., June 1, 2009; 33(6): 1338 - 1344. [Abstract] [Full Text] [PDF]

				A. Dirksen, E. Piitulainen, D. G. Parr, C. Deng, M. Wencker, S. B. Shaker, and R. A. Stockley Exploring the role of CT densitometry: a randomised study of augmentation therapy in {alpha}1-antitrypsin deficiency Eur. Respir. J., June 1, 2009; 33(6): 1345 - 1353. [Abstract] [Full Text] [PDF]

				C. P. Hersh, D. L. DeMeo, and E. K. Silverman National Emphysema Treatment Trial State of the Art: Genetics of Emphysema Proceedings of the ATS, May 1, 2008; 5(4): 486 - 493. [Abstract] [Full Text] [PDF]

				G. Tirado-Conde, B. Lara, and M. Miravitlles Augmentation therapy for emphysema due to alpha-1-antitrypsin deficiency Therapeutic Advances in Respiratory Disease, February 1, 2008; 2(1): 13 - 21. [Abstract] [PDF]

				J. B. Wilk, A. Herbert, C. M. Shoemaker, D. J. Gottlieb, and S. Karamohamed Secreted Modular Calcium-binding Protein 2 Haplotypes Are Associated with Pulmonary Function Am. J. Respir. Crit. Care Med., March 15, 2007; 175(6): 554 - 560. [Abstract] [Full Text] [PDF]

				S. G. Louie, D. A. Sclar, and M. A. Gill Aralast: A New {alpha}1-Protease Inhibitor for Treatment of {alpha}-Antitrypsin Deficiency Ann. Pharmacother., November 1, 2005; 39(11): 1861 - 1869. [Abstract] [Full Text] [PDF]

				J. K. Stoller, J. Tomashefski Jr, R. G. Crystal, A. Arroliga, C. Strange, D. N. Killian, M. D. Schluchter, H. P. Wiedemann, and for the α1-Antitrypsin Deficiency Registry S Mortality in Individuals With Severe Deficiency of α1-Antitrypsin: Findings From the National Heart, Lung, and Blood Institute Registry Chest, April 1, 2005; 127(4): 1196 - 1204. [Abstract] [Full Text] [PDF]

				R A Sandhaus {alpha}1-Antitrypsin deficiency {middle dot} 6: New and emerging treatments for {alpha}1-antitrypsin deficiency Thorax, October 1, 2004; 59(10): 904 - 909. [Abstract] [Full Text] [PDF]

				J K Stoller and L S Aboussouan {alpha}1-Antitrypsin deficiency {middle dot} 5: Intravenous augmentation therapy: current understanding Thorax, August 1, 2004; 59(8): 708 - 712. [Abstract] [Full Text] [PDF]

				J K Stoller {alpha}1-Antitrypsin deficiency Thorax, February 1, 2004; 59(2): 92 - 93. [Full Text] [PDF]

				American Thoracic Society/European Respiratory Society Statement: Standards for the Diagnosis and Management of Individuals with Alpha-1 Antitrypsin Deficiency Am. J. Respir. Crit. Care Med., October 1, 2003; 168(7): 818 - 900. [Full Text] [PDF]

				J. K. Stoller, R. Fallat, M. D. Schluchter, R. G. O'Brien, J. T. Connor, N. Gross, K. O'Neil, R. Sandhaus, and R. G. Crystal Augmentation Therapy With {alpha}1-Antitrypsin: Patterns of Use and Adverse Events Chest, May 1, 2003; 123(5): 1425 - 1434. [Abstract] [Full Text] [PDF]

				A. M. Cantin, D. E. Woods, D. Cloutier, E. K. Dufour, and R. Leduc Polyethylene Glycol Conjugation at Cys232 Prolongs the Half-Life of {alpha}1 Proteinase Inhibitor Am. J. Respir. Cell Mol. Biol., December 1, 2002; 27(6): 659 - 665. [Abstract] [Full Text] [PDF]

				J. K. Stoller, F. Rouhani, M. Brantly, S. Shahin, R. A. Dweik, J. M. Stocks, J. Clausen, E. Campbell, and F. Norton Biochemical Efficacy and Safety of a New Pooled Human Plasma {alpha}1-Antitrypsin, Respitin* Chest, July 1, 2002; 122(1): 66 - 74. [Abstract] [Full Text] [PDF]

				J. G. W. Burdon, S. Brenton, M. Ayad, K. Knight, and J. Lieberman Augmentation Therapy in {alpha}1-Antitrypsin Deficiency Chest, August 1, 2001; 120(2): 687 - 687. [Full Text] [PDF]

				R A PRIMHAK and M S TANNER Alpha-1 antitrypsin deficiency Arch. Dis. Child., July 1, 2001; 85(1): 2 - 5. [Full Text] [PDF]

				J. Kropp, M. Wencker, A. Hotze, N. Banik, G. E. Hübner, G. Wunderlich, E. Ulbrich, N. Konietzko, and H.-J. Biersack Inhalation of [123I]{{alpha}}1-Protease Inhibitor: Toward a New Therapeutic Concept of {{alpha}}1-Protease Inhibitor Deficiency? J. Nucl. Med., May 1, 2001; 42(5): 744 - 751. [Abstract] [Full Text]

				R. A. Sandhaus {{alpha}}1-Antitrypsin Deficiency Therapy : Pieces of the Puzzle Chest, March 1, 2001; 119(3): 676 - 678. [Full Text] [PDF]

				M. Wencker, B. Fuhrmann, N. Banik, and N. Konietzko Longitudinal Follow-up of Patients With {{alpha}}1-Protease Inhibitor Deficiency Before and During Therapy With IV {{alpha}}1-Protease Inhibitor Chest, March 1, 2001; 119(3): 737 - 744. [Abstract] [Full Text] [PDF]

				J. Lieberman Augmentation Therapy Reduces Frequency of Lung Infections in Antitrypsin Deficiency : A New Hypothesis With Supporting Data Chest, November 1, 2000; 118(5): 1480 - 1485. [Abstract] [Full Text] [PDF]

				J. S. Wilson and J. R. Galvin Normal Diffusing Capacity in Patients With PiZ {alpha}1-Antitrypsin Deficiency, Severe Airflow Obstruction, and Significant Radiographic Emphysema Chest, September 1, 2000; 118(3): 867 - 871. [Abstract] [Full Text] [PDF]

				R A Stockley Alpha-1-antitrypsin deficiency: what next? Thorax, July 1, 2000; 55(7): 614 - 618. [Full Text]

				S. A. Alkins and P. O’Malley Should Health-Care Systems Pay for Replacement Therapy in Patients With {alpha}1-Antitrypsin Deficiency?: A Critical Review and Cost-Effectiveness Analysis Chest, March 1, 2000; 117(3): 875 - 880. [Abstract] [Full Text] [PDF]

				M. D. SCHLUCHTER, J. K. STOLLER, A. F. BARKER, A. SONIA BUIST, R. G. CRYSTAL, J. F. DONOHUE, R. J. FALLAT, G. M. TURINO, C. E. VREIM, and M. C. WU Feasibility of a Clinical Trial of Augmentation Therapy for alpha 1-Antitrypsin Deficiency Am. J. Respir. Crit. Care Med., March 1, 2000; 161(3): 796 - 801. [Abstract] [Full Text] [PDF]

				A. DIRKSEN, J. H. DIJKMAN, F. MADSEN, B. STOEL, D. C. S. HUTCHISON, C. S. ULRIK, L. T. SKOVGAARD, A. KOK-JENSEN, A. RUDOLPHUS, N. SEERSHOLM, et al. A Randomized Clinical Trial of alpha 1-Antitrypsin Augmentation Therapy Am. J. Respir. Crit. Care Med., November 1, 1999; 160(5): 1468 - 1472. [Abstract] [Full Text]

				P. J. BARNES Novel Approaches and Targets for Treatment of Chronic Obstructive Pulmonary Disease Am. J. Respir. Crit. Care Med., November 1, 1999; 160(5): S72 - 79. [Abstract] [Full Text] [PDF]

				M. Miravitlles, J. de Gracia, M.-J. Rodrigo, M.-J. Cruz, M. Vendrell, R. Vidal, and F. Morell Specific Antibody Response Against the 23-Valent Pneumococcal Vaccine in Patients With {alpha}1-Antitrypsin Deficiency With and Without Bronchiectasis Chest, October 1, 1999; 116(4): 946 - 952. [Abstract] [Full Text] [PDF]

				J K STOLLER Augmentation therapy for severe alpha 1-antitrypsin deficiency: is the jury still out on a trial? Thorax, December 1, 1998; 53(12): 1007 - 1009. [Full Text]

				The Alpha-1-Antitrypsin Deficiency Registry Study  Survival and FEV1 Decline in Individuals with Severe Deficiency of alpha 1-Antitrypsin Am. J. Respir. Crit. Care Med., July 1, 1998; 158(1): 49 - 59. [Abstract] [Full Text] [PDF]